Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany *

Martin Lindner1†, Gwendolyn Gramer1†, Gisela Haege1, Junmin Fang-Hoffmann1, Karl O Schwab2, Uta Tacke2, Friedrich K Trefz3, Eugen Menge1, Udo Wendel5, Michael Leichsenring6, Peter Burgard1† and Georg F Hoffmann1†

Abstract

Background: National newborn screening programmes based on tandem-mass spectrometry (MS/MS) and other newborn screening (NBS) technologies show a substantial variation in number and types of disorders included in the screening panel. Once established, these methods offer the opportunity to extend newborn screening panels without significant investment and cost. However, systematic evaluations of newborn screening programmes are rare, most often only describing parts of the whole process from taking blood samples to long-term evaluation of outcome.

Methods: In a prospective single screening centre observational study 373 cases with confirmed diagnosis of a metabolic disorder from a total cohort of 1,084,195 neonates screened in one newborn screening laboratory between January 1, 1999, and June 30, 2009 and subsequently treated and monitored in five specialised centres for inborn errors of metabolism were examined. Process times for taking screening samples, obtaining results, initiating diagnostic confirmation and starting treatment as well as the outcome variables metabolic decompensations, clinical status, and intellectual development at a mean age of 3.3 years were evaluated.

Results: Optimal outcome is achieved especially for the large subgroup of patients with medium-chain acyl-CoA dehydrogenase deficiency. Kaplan-Meier-analysis revealed disorder related patterns of decompensation. Urea cycle disorders, organic acid disorders, and amino acid disorders show an early high and continuous risk, medium-chain acyl-CoA dehydrogenase deficiency a continuous but much lower risk for decompensation, other fatty acid oxidation disorders an intermediate risk increasing towards the end of the first year. Clinical symptoms seem inevitable in a small subgroup of patients with very early disease onset. Later decompensation can not be completely prevented despite pre-symptomatic start of treatment. Metabolic decompensation does not necessarily result in impairment of intellectual development, but there is a definite association between the two.

Conclusions: Physical and cognitive outcome in patients with presymptomatic diagnosis of metabolic disorders included in the current German screening panel is equally good as in phenylketonuria, used as a gold standard for NBS. Extended NBS entails many different interrelated variables which need to be carefully evaluated and optimized. More reports from different parts of the world are needed to allow a comprehensive assessment of the likely benefits, harms and costs in different populations.

Keywords: newborn screening, tandem-mass spectrometry
**Introduction**

The advent of tandem mass spectrometry (MS/MS) allowed for a substantial increase in the number of disorders included in the newborn screening (NBS) panel [1]. At present national NBS programmes differ widely. The American College of Clinical Genetics proposed 29 core and 25 secondary conditions [2], the German panel includes 12 metabolic disorders [3], the United Kingdom (UK) screens for phenylketonuria and medium-chain acyl-CoA dehydrogenase deficiency [4], France for phenylketonuria only [5], and Hongkong for no metabolic disorder but hypothyroidism [6]. Recommendations for the screening process also vary, e.g. for time of blood sampling between 24 hours (USA), 48 to 72 hours (Germany) to 120 hours (UK). Laboratory cut-offs and algorithms for confirmatory diagnostics are also not standardised.

Although the criteria proposed by Wilson and Jungner in 1968 [7] for NBS programmes are still accepted [2], they have been modified mainly driven by new technologies but without systematic evaluation of treatment and outcome yet [8]. Programme effectiveness, quality assurance and programme evaluation have been suggested as amendments to the Wilson and Jungner criteria [9,10].

**Patients and methods**

**Panel of screened disorders**

During a pilot period from January 1999 until April 2005 the panel of disorders was not officially regulated in Germany, and all disorders recommended in the US panel were screened for in our centre (N = 583,553 neonates). In December 2004 the regulatory authority for NBS was transferred to a national commission resulting in an officially implemented panel of 12 defined metabolic disorders to be exclusively screened from May 2005 onwards (N = 500,642 neonates) (Table 1). At the same time written informed consent became mandatory. The recommended time for blood sampling was between day of life three to five before 2002 and between 36 and 72 hours thereafter [11].

**Population**

Between January 1, 1999 and June 30, 2009, the NBS centre of the University of Heidelberg analysed dried blood spots of 1,084,195 neonates from three South-Western German states. Ninety percent of NBS samples were sent from obstetric units or children’s hospitals and 10% from midwives or general paediatricians. MS/MS NBS was performed as described previously in a preliminary report from our centre [12].

**Cases with confirmed diagnosis of a metabolic disorder**

In 377 cases confirmatory diagnostics was recommended. A metabolic disorder was confirmed in 373 cases. Minimal criteria for accepting a diagnosis as confirmed are stated in Table 1. In four cases a disorder was suspected, but further confirmatory investigation was not possible due to early death (one suspicion of tyrosinaemia type I, one of medium-chain acyl-CoA dehydrogenase deficiency) or because cases were lost to follow-up (one suspicion of methylmalonic aciduria, one of carnitine transporter deficiency) (Table 1). Maternal 3-methylcrotonyl-CoA carboxylase deficiency was diagnosed in 6 of the 373 cases. To our knowledge there has been no false negative screening result. Positive screens were communicated by phone as well as by fax and/or mail for all samples but for hyperphenylalaninaemias, where a second sample was only requested by fax and/or mail. The study sample was subdivided into three groups: Group 1 (NBS) comprised 355 neonates with a high suspicion of a metabolic disorder resulting from regular NBS, group 2 (symptomatic) contained 11 patients diagnosed because of clinical symptoms before NBS blood sample was taken or before NBS result was available. In group 3 (high risk, 11 patients) specific metabolic analyses were performed immediately after birth (n = 10) or even prenatally (n = 1) due to a known family risk. Eighty percent of neonates screened positive were further investigated in seven specialised metabolic units versus 20% in local Paediatric departments.

**Process evaluation**

377 data sets could be analysed for process times and process durations (Table 1). The screening process was analysed in five sequential steps from blood sampling (step 1), report of first screening result (step 2), start of confirmatory testing (step 3), confirmation of result (step 4), and start of treatment (step 5). Process times were calculated as the child’s age at a particular step (days/hours for steps 1 and 2; days for steps 3 to 5) and ‘process duration’ as the time difference between steps. ‘Start of confirmation’ was defined as the start of specific investigations, except for mild hyperphenylalaninaemia, for which start of confirmation was defined as the time of the first repeat specimen.

**Outcome evaluation**

The target sample for outcome evaluation included 257 cases in group 1 (excluding 88 babies with mild hyperphenylalaninaemia, six babies of mothers with maternal 3-methylcrotonyl-CoA carboxylase deficiency, four non-definitely confirmed cases), 11 patients in group 2, and 11 patients in group 3. Ten patients were soon lost to follow-up (one carnitine palmitoyltransferase II deficiency, two medium-chain acyl-CoA dehydrogenase deficiency, three short-chain acyl-CoA dehydrogenase deficiency, one biotinidase deficiency, one galactosaemia, two phenylketonuria), one patient with mitochondrial tri-functional protein deficiency deceased at the age of six
| Disorder                                  | N Group 1 | Group 2 | Group 3 | Treatment                                                                 |
|------------------------------------------|-----------|---------|---------|---------------------------------------------------------------------------|
| PKU<sup>a</sup>                          | 85        | 84      | 1<sup>b</sup> | Blood phenylalanine ≥ 600 μmol/L, normal urinary pterins and DBS dihydropteridine reductase activity |
| MHP<sup>a</sup>                          | 88        | 88      | 2       | First and control phenylalanine levels < 600 μmol/L, phenylalanine/tyrosine < 3, normal urinary pterins and DBS dihydropteridine reductase activity |
| PTPS<sup>a</sup>                         | 1         | 1       |         | Characteristic pterin profile in urine                                    |
| MSUD<sup>a</sup>                         | 7         | 4       | 1       | Elevated branched-chain amino acids including alloisoleucine              |
| TYR I<sup>e</sup>                        | 2         | 2       |         | Elevated succinylacetone in urine                                        |
| Homocystinuria<sup>a</sup>               | 0         |         |         | Characteristic profile of homocysteine, methionine, cysteine in plasma    |
| NKH<sup>a</sup>                          | 1         | 1       |         | Elevated glycine in plasma and CSF and pathological ratio plasma/CSF glycine |
| GT I classic<sup>a</sup>                 | 4         | 1       | 3       | Characteristic amino acid profile in plasma and ammonia in blood          |
| GT I mild<sup>a</sup>                    | 6         | 6       | 1       | Characteristic amino acid profile in plasma and ammonia in blood, molecular genetic analysis |
| ASLD<sup>a</sup>                         | 1         | 1       | 1       | Characteristic amino acid profile in plasma and urine                     |
| Arginase deficiency<sup>a</sup>          | 0         |         |         | Enzyme deficiency in erythrocytes                                         |
| Fatty acid oxidation disorders           |           |         |         |                                                                            |
| CPT ID<sup>e</sup>                       | 1         | 1       |         | Enzyme deficiency in fibroblasts                                          |
| CPT IID<sup>e</sup>                      | 1         | 1       |         | Enzyme deficiency in fibroblasts                                          |
| CACTD<sup>e</sup>                        | 0         |         |         | Enzyme deficiency in fibroblasts                                          |
| CTD<sup>e</sup>                          | 3         | 3       | 3       | Pathological tubular carnitine reabsorption, fibroblast transport studies |
| MCADD<sup>e</sup>                        | 81        | 77      | 2       | Characteristic acylcarnitine profile in plasma/DBS and/or hexanoylglycine in urine and/or informative genotype |
| LCHADD<sup>a</sup>/mTEF<sup>a</sup>        | 6         | 5       | 1       | Characteristic acylcarnitine profile in plasma/DBS and/or informative genotype and/or enzyme activity |
| VLCADD<sup>a</sup>                       | 6         | 6       | 6       | Characteristic acylcarnitine profile in plasma/DBS and/or enzyme activity in lymphocytes or fibroblasts and/or informative genotype |
| SCADD<sup>a</sup>                        | 9         | 9       | 3       | Characteristic acylcarnitine profile in plasma/DBS and ethylmalonic acid in urine and enzyme activity |
| MADD<sup>a</sup>                         | 3         | 3       | 2       | Characteristic profiles of acylcarnitines in plasma and organic acids in urine |
| Organic acid disorders                    |           |         |         |                                                                            |
| GA<sup>a</sup>                           | 6         | 6       | 6       | Characteristic urinary organic acid profile, informative genotype         |
| IVA classic<sup>a</sup>                  | 5         | 4       | 1       | Characteristic urinary organic acid profile                              |
| IVA mild<sup>a</sup>                     | 10        | 9       | 1       | Characteristic urinary organic acid profile, informative genotype         |
| MBD<sup>f</sup>                          | 0         |         |         | Characteristic urinary organic acid profile                              |
| MMA/Cbl<sup>e</sup>                      | 4         | 3       | 1       | Characteristic urinary organic acid profile +/- abnormal concentrations of plasma homocysteine and methionine (complementation studies in fibroblasts in all patients) |
| PA<sup>e</sup>                           | 4         | 3       | 1       | Characteristic urinary organic acid profile                              |
| 3-MCCD<sup>e</sup>                       | 8         | 8       | 5       | Characteristic urinary organic acid profile                              |
| MBH<sup>e</sup>                          | 0         |         |         | Characteristic urinary organic acid profile, informative genotype         |
| MGA<sup>e</sup>                          | 0         |         |         | Characteristic urinary organic acid profile, informative genotype         |
months and one with non-ketotic hyperglycaemia in the neonatal period, four were too young for outcome evaluation (≤1 year) and parents of 16 newborns did not give consent. Therefore 247 patients were eligible for outcome evaluation. Following a standardised protocol, paediatric metabolic specialists and psychologists evaluated the clinical outcome by the number of metabolic decompensations, dysfunction of selected organs, growth disturbances, standardised IQ tests (1.5 yrs Denver test, 3.5 yrs K-ABC or HAWIK-IV) as well as school placement. Metabolic decompensation was defined as any event resulting in hospitalization after a patient showed biochemical markers of metabolic ‘derangement’ or clinical signs of deterioration.

Data management and statistics

Screening data were taken from the database of the NBS centre. Confirmatory diagnostics and outcome data were retrieved from patients’ files. All data were entered in standardised forms by the authors (GG, ML, PB, UW), transferred to the study’s data base by a data manager (Microsoft Access 2003), checked for consistency and correctness and analyzed with SPSS Version 16.

Results

Part 1: Process analysis

Data sets including all five process steps were available for 205 confirmed cases. Median ages (interquartile ranges) were 2.9 days (2.34-4.00) for blood sampling (step 1), 7.1 days (5.7-9.2) for the first report of the screening result (step 2), 9.0 days (7.0-12.0) for start of treatment (step 5). 75% of all screening processes reflecting that for mild hyperphenylalaninaemia requests of the pathological profile in the newborn.

| Table 1 Patient sample, diagnostic criteria and treatment modalities (Continued) |
|---------------------------------|---------------------------------|
| HCSD  | 0 | Characteristic urinary organic acid profile, enzyme deficiency |
| BIOD  | 9 | Enzyme deficiency in DBS and/or serum |
| KTD  | 0 | Characteristic profiles of acylcarnitines in plasma and organic acids in urine |
| HMG-CoA LD  | 1 | Characteristic profiles of acylcarnitines in plasma and organic acids in urine |

Other disorders

| Galactosaemia | 14 | 9 | 2 | Enzyme deficiency and elevated galactose-1-phosphate in DBS and erythrocytes |

Others conditions

| Maternal 3-MCCD | 6 | 6 | 6 | Characteristic acylcarnitine profile in plasma/DBS of mother and clearing of the pathological profile in the newborn |

Not confirmed | 4 | 4 | 3 | 1 |  |

Total | 377 | 355 | 11 | 11 | 239 | 82 | 56 |

Abbreviations: ASLD = Argininosuccinate lyase deficiency; BIOD = Biotinidase deficiency; CACTD = Carnitine acylcarnitine translocase deficiency; CIT I = Citrullinaemia type I; CPT ID = Carnitine palmitoyltransferase I deficiency; CPT IID = Carnitine palmitoyltransferase II deficiency; CTD = Carnitine transporter deficiency; ISC = Isocitrato dehydrogenase deficiency; LCHADD = Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; mTFP = mitochondrial tri-functional protein deficiency; MADD = Multiple acyl-CoA dehydrogenase deficiency; MCADD = Medium-chain acyl-CoA dehydrogenase deficiency; MBD = 2-Methylbutyryl-CoA dehydrogenase deficiency; MGA = 3-Methylglutaconic aciduria; MHBD = 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency; MHP = Maple syrup urine disease; MMA/Cbl = Methylmalonic aciduria (all kinds); MSUD = Maple syrup urine disease; NRK = Non-ketotic hyperglycaemia; PA = Propionic aciduria; PKU = Phenylketonuria; PTPSD = 6-Pyruvoyltetrahydropterin synthase deficiency; SCADD = Short-chain acyl-CoA dehydrogenase deficiency; TYR I/III = Tyrosinaemia type I/III; VLCADD = Very long-chain acyl-CoA dehydrogenase deficiency.
and group 3 (high risk) were significant for age at start of NBS or specific metabolic analyses ($\chi^2(2, N = 236) = 38.75; p < 0.001$), age at confirmed result ($\chi^2(2, N = 234) = 25.77; p < 0.001$), and age at start of treatment ($\chi^2(2, N = 230) = 30.11; p < 0.001$) with all process times being later for group 2 than for group 3, but still earlier than for group 1. Disease specific treatment (in group 1) or supportive treatment (in group 2) often started before confirmation of diagnosis. Only in two symptomatic patients (one medium-chain acyl-CoA dehydrogenase deficiency, one galactosaemia) NBS was faster than the results of specific diagnostic investigations (Table 2). In phenylketonuria immediate start of treatment is not necessary and would even interfere with confirmatory testing. Treatment in phenylketonuria patients started less often before confirmation of diagnosis (27%) than in disorders at risk for acute metabolic decompensation (42%) (Fisher’s exact test $p = 0.03$).

Part 2: Outcome analysis

**Metabolic decompensations**

Disorders were classified according to their risk of developing decompensation or not (see Table 1). Information on metabolic decompensation was available for 133 patients with a potentially decompensating disorder. At least one metabolic decompensation was reported for 34 (25.6%) patients: 19 out of 113 (16.8%) patients in group 1 (NBS) (see Table 1) suffered one or more decompensations, all 11 patients (100%) in group 2 (symptomatic) had altogether 28 decompensations and four out of nine patients (44%) in group 3 (high risk) had altogether 17 decompensations. All patients with classical urea cycle disorders (5/5 patients; four citrullinaemia type I, one argininosuccinate lyase deficiency) experienced at least one metabolic crisis, followed by amino acid disorders (5/10 patients; decompensations only in maple syrup urine disease), galactosaemia (6/13 patients), organic acid disorders (8/20 patients: three isovaleric aciduria, two propionic aciduria, one cobalamin C/D defect, one 3-hydroxy-3-methylglutaryl-CoA lyase deficiency, one glutaric aciduria type I), and fatty acid oxidation disorders (10/85 patients: six medium-chain acyl-CoA dehydrogenase deficiency, three long-chain 3-hydroxy-acyl-CoA dehydrogenase deficiency, one very long-chain acyl-CoA dehydrogenase deficiency). The highest number of decompensations per individual patient was observed in patients with classical citrullinaemia (one patient with six decompensations), propionic aciduria (one patient with seven decompensations) and argininosuccinate lyase deficiency (one patient with ten decompensations).

Comparison of four groups of disorders (1) mild citrullinaemia ($n = 4$) and mild isovaleric aciduria ($n = 10$), (2) medium-chain acyl-CoA dehydrogenase deficiency ($n = 69$), (3) fatty acid oxidation disorders other than medium-chain acyl-CoA dehydrogenase deficiency (six very long-chain acyl-CoA dehydrogenase deficiency, four long-chain acyl-CoA dehydrogenase deficiency, two carnitine transporter deficiency, three multiple acyl-CoA dehydrogenase deficiency, one carnitine palmitoyltransferase I deficiency), and (4) urea cycle disorders (five citrullinaemia type I classic, one argininosuccinate lyase deficiency), organic acid disorders (six glutaric aciduria type I, five isovaleric aciduria classic, four propionic aciduria, four methylmalonic acidurias, one 3-hydroxy-3-methylglutaryl-CoA lyase deficiency), and amino acid...

### Table 2 Process times for patients who became symptomatic before first blood sampling or before the first screening result was available

| Diagnosis            | Age at decompensation (days) | Age at blood sampling 1st screening card (days) | Age at 1st screening result (days) | Age at con- confirmed diagnosis (days) | Age at start of treatment (days) |
|----------------------|------------------------------|-----------------------------------------------|-----------------------------------|---------------------------------------|---------------------------------|
| MCADD                | 0.0                          | 4.0                                           | 11.0                              | 12.0                                  | 14.0                            |
| MCADD                | 3                            | 1.7                                           | 6.8                               | 6.0                                   | 3.0                             |
| CIT I classic        | 1.0                          | 3.0                                           | 12.0                              | 2.0                                   | 2.0                             |
| CIT I classic        | 1.0                          | 3.0                                           | 10.0                              | 5.0                                   | Not available                   |
| CIT I classic        | 2.0                          | 2.7                                           | 8.6                               | 2.0                                   | 2.0                             |
| IVA classic          | 3.0                          | 4.4                                           | 10.7                              | 8.0                                   | 8.0                             |
| PA                   | 3.0                          | 3.0                                           | 16.0                              | 3.0                                   | 3.0                             |
| Cobalamin C/D defect | 3.0                          | 5.0                                           | 15.0                              | 5.0                                   | 5.0                             |
| Galactosaemia        | 4.0                          | 3.5                                           | 7.0                               | 8.0                                   | 7.0                             |
| Galactosaemia        | 8.0                          | 4.2                                           | 11.1                              | 9.0                                   | 9.0                             |
| MSUD                 | 4.0                          | 3.4                                           | 9.3                               | 5.0                                   | 5.0                             |

Abbreviations see Table 1

Bold text indicates that the first screening result arrived after confirmed diagnosis.
disorders (seven maple syrup urine disease, two tyrosinaemia type I, one 6-pyruvoyltetrahydropterin synthase deficiency) regarding their patterns of metabolic decompensation revealed a clear cut order of severity (0%, 9%, 25%, 50% decompensations, Figure 1). Kaplan-Meier analysis Mantel-Cox Log Rank test was significant for comparison between groups (1) vs. (4) ($\chi^2 = 9.6; p = 0.002$), (1) vs. (3) ($\chi^2 = 4.0; p <0.05$), and (4) vs. (2) ($\chi^2 = 26.4; p <0.0001$), showed trends for (2) vs. (3) ($\chi^2 = 3.0; p = 0.083$) and (3) vs. (4) ($\chi^2 = 3.5; p = 0.061$). The difference between (1) and (2) was not significant ($\chi^2 = 1.3; p = 0.260$).

Clinical signs, cognitive outcome and school placement

Standardised clinical status examination investigated 32 clinically relevant signs related to central nervous system, peripheral nervous system, muscle, heart, eye, liver, skin, kidney, haematopoiesis and growth. For each disorder critical subsets of signs were defined (Additional file 1). Patients with $\geq 1$ sign received a positive clinical status score. For 75 patients with decompensation disorders and 50 patients with phenylketonuria (total 125) at least one status evaluation was available. Out of the 75 patients with decompensation disorders, 19 (25.3%) were scored positive. Table 3 shows the highest rate of positive clinical status in symptomatically diagnosed patients (50%), while phenylketonuria and medium-chain acyl-CoA dehydrogenase deficiency had similarly low scores. Nine of 48 (18.7%) patients with a decompensation disorder but without decompensation had $\geq 1$ sign compared with ten of 27 (37%) patients with at least one metabolic decompensation (OR: 2.55; 95% CI [0.88; 7.40]).

Standardised psychological assessment was done in 120 patients at a mean age of 3.3 years (SD = 1.9). Psychometric results were scored as subnormal for IQ results < 85. In the group of 70 patients with a decompensating disorder, 4 out of 44 (9.1%) without decompensation had a subnormal outcome compared with 6 out of 26 (23.1%) with at least one decompensation (OR: 3.00; 95% CI [0.76; 11.86]).

School placement is only known for 24 of 28 patients equal or older than 6 years (the target age for formal schooling in Germany). All patients with medium-chain acyl-CoA dehydrogenase deficiency (9/9) or with phenylketonuria (7/7) attend normal schools. For the more severe disorders 3/8 are not able to attend normal schools.

In the group of patients with medium-chain acyl-CoA dehydrogenase deficiency genotype was known for 28 patients. Of these 16 were homozygous for the common mutation c.985A $>$G (K329E). Metabolic decompensations were observed in 6 patients. In five of these, the results of neurological status and IQ tests were normal on follow up. One patient showed normal intellectual and physical development, but slight myocloni on neurological examination. The only patient in our cohort with medium-chain acyl-CoA dehydrogenase deficiency who showed severe neurological and intellectual impairment (IQ 74) never experienced a metabolic decompensation. However, he presented with severe neonatal onset cardiomyopathy, which seems to be part of a syndromatic condition and unrelated to medium-chain acyl-CoA dehydrogenase deficiency.

![Figure 1 Kaplan-Meier analysis of decompensations in disjunct subsamples of (1) mild isovaleric aciduria and mild citrullinaemia (Mild IVA, mild CIT), (2) medium-chain acyl-CoA dehydrogenase deficiency (MCADD), (3) other fatty acid oxidation disorders (FAOD), and (4) urea cycle, organic acid and amino acid disorders (UCD, OA, AA).](http://www.ojrd.com/content/6/1/44)
Comparison of disorders of the screening panel 2005 without phenylketonuria as well as biotinidase deficiency versus disorders additionally screened until 2005 showed significant differences for clinical status (OR: 24.3; 95% CI [5.5; 106]), as well as for IQ results (OR: 9.2; 95% CI [2.41]). Comparison of disorders of the screening panel 2005 without phenylketonuria and biotinidase deficiency versus phenylketonuria alone did not reveal any significant differences, neither for clinical status scores (OR: 0.9; 95% CI [0.3; 2.8]) nor for IQ results (OR: 1.0; 95% CI [0.3; 4.0]). Standardised clinical status was significantly associated with psychometric results in decompensation disorders (C = 0.44; p < 0.001) as well as in phenylketonuria patients (C = 0.46; p < 0.01).

Discussion

1,084,195 newborns screened in our centre correspond to about 1.6 times the annual birth rate in Germany. As far as we know this is the first prospective single centre evaluation of a NBS programme utilizing MS/MS. Numerous publications describe the epidemiology, technical aspects and clinical validity of MS/MS screening while there are only a few retrospective evaluations of NBS programmes. Only the Australian screening programme provides data on similar aspects of overall test performance for groups of disorders as well as of follow-up results [13].

In our cohort 75% of all patients started treatment within the first 13 days of life. Out of 133 patients at risk for episodes of decompensation 11 (8%) presented clinically before the screening result was available. Even taking blood samples at 24 hrs after birth and optimal further processing of specimens would not have prevented most of these patients from early adverse events (Table 2). Kaplan-Meier-analysis revealed disorder related patterns of early and late decompensations (Figure 1). Urea cycle disorders, organic acid disorders, and amino acid disorders show the highest, earliest and continuous risk. Patients with medium-chain acyl-CoA dehydrogenase deficiency have a continuous but much lower risk for episodes of decompensation, and other fatty acid oxidation disorders an intermediate risk starting towards the end of the first year (with first intercurrent illness and/or missing feeds).

In medium-chain acyl-CoA dehydrogenase deficiency NBS leads to prevention of metabolic decompensations and neurological harm in nearly all patients [14,15], compared to 40 to 74% presenting with severe illness, 16-26% with early death and 20% developing severe neurological impairment in unscreened populations [16-18]. This benefit remains relevant although the number of MCADD cases detected is almost doubled by NBS. However, contemporary patients from unscreened cohorts surviving metabolic decompensations also showed normal neurological outcome, most probably due to improved awareness and emergency treatment [13].

Our data correspond well to those of the Australian study [13] for the common set of disorders as well as for medium-chain acyl-CoA dehydrogenase deficiency alone, except for the prevalence of symptomatic cases presenting during the first days of life (Table 4). One patient showed normal intellectual and physical development, but slight myocloni on neurological examination. As the patient’s mother showed similar symptoms, these are most probably unrelated to medium-chain acyl-CoA dehydrogenase deficiency. In his brother, also with medium-chain acyl-CoA dehydrogenase deficiency, mild muscular hypotonia without any practical consequences in everyday life was observed during the standardized
examination. For comparison with the results of the Australian study both ratings were judged as “nil significant”. In the present study 11 out of 1,084,195 children presented clinically before the screening result was available compared to 12 of 461,500 in the Australian screened cohort (OR: 0.39; 95% CI [0.17; 0.88]). Both studies document the value of extended newborn screening mainly on the basis of medium-chain acyl-CoA dehydrogenase deficiency, a disease of European origin.

Using phenylketonuria as a gold standard, patients with metabolic disorders included in the German 2005 screening panel achieved similarly good outcome data, whereas the outcome of the set of disorders screened additionally until 2005 was significantly worse than the outcome of the 2005 screening panel. Not including these disorders as a group into the screening panel could be defended as rational, although numbers are too small to draw conclusions for single disorders.

Evaluation of diseases with much lower frequencies can benefit from national and international collaboration, as could be shown for glutaric aciduria type I [19,20], as well as from comparison with historical controls, well designed “n-of-1” trials and translational research [21]. Systematic follow-up is also necessary to solve the question of mild phenotypes probably representing non-diseases.

Although unnecessary treatment of mild phenotypes of metabolic disorders is a serious problem [22], it seems unjustified to attribute the issue exclusively to NBS. Considering screening as a programme there are multiple steps to identify mild variants and revise treatment decisions. Sampling time and cut-offs influence detection rates of mild variants and the same is true for methods and cut-offs of confirmatory procedures. Duarte galactosaemia needs no further investigation and no reporting [23], but unfortunately this is not yet known for most other disorders. Therefore evaluation of the whole process including follow-up is necessary. Earlier sampling may allow earlier detection of some disorders e.g. maple syrup urine disease, but also increases the risk of missing others e.g. homocystinuria.

The principle that population screening requires a structured evaluation has been recently set in place by the US Health and Human Services Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC) instituting a permanent review panel in 2007 [24]. Five criteria have been defined to add a condition to the NBS panel: sufficient information about the condition itself, evidence regarding appropriate screening tests, diagnostic methods, treatment and economic evaluations. In the European Union an evaluation process was recently initiated with the tender No. EAHC/2009/Health/09 ‘Evaluation of population newborn screening practices for rare disorders in Member States of the European Union’ [25]. Reports on NBS programmes from different parts of the world are necessary to allow a comprehensive assessment of benefits, harms and costs of NBS programs [26]. As prevalences are likely to be different in populations of diverse ethnic background, pilot projects in individual countries will contribute important information [27,28].

### Table 4 Comparison of data across studies

| Prevalence group | Wilcken et al., 2009 [13] | This study | OR; 95% CI |
|------------------|--------------------------|------------|------------|
| **Prevalence group 1** | | | |
| MSUD, BIOD, GA I, IVA, MCADD, CACTD, CPT ID, CPT II, LCHADD, VLCADD | n = 37 | n = 122 | 1.40; [0.97;2.02] |
| | 8.0:100,000 | 11.25: 100,000 | |
| **Prevalence group 2** | Group 1 without MCADD | | 1.34; [0.72;2.51] |
| | n = 13 | n = 41 | |
| | 28.100,000 | 3.8: 100,000 | |
| MCADD | | | |
| Prevalence | n = 24 | n = 81 | 1.44; [0.91;2.27] |
| | 5.2: 100,000 | 7.5: 100,000 | |
| Clinical presentation by day 5 | N = 2 | N = 2 | |
| Asymptomatic or clinical presentation after day 5 | N = 22 | N = 79 | |
| Metabolic decompensation during follow-up | Not reported | 6/69 | |
| Physical score nil significant at 6 (Australia)/3 (Heidelberg) years | 22/22 | 31*32 | |
| | 22/22 | 31*32 | |
| No intellectual handicap at 6 (Australia)/3 (Heidelberg) years (IQ or intellectual development in normal range (IQ≥85)) | | |
| Normal school at ~6 yrs | 15/15 | 9/9 | |

* one patient never showing a metabolic decompensation but congenital cardiomyopathy of unknown origin. The clinical signs of two of three MCADD patients with a “positive” clinical status score (Table 3) were judged as non significant (see text).
Arabic Gulf country Qatar the overall frequency of metabolic disorders detected by the particular NBS program is much higher (1:966) compared to the present study (1:2920), and prevalence in a Turkish pilot study was 1:839 [29] illustrating a presumably likely high benefit of extended NBS in Turkey, Middle East and North African countries. In contrast the first comprehensive report from an East Asian country, Taiwan, revealed a prevalence of 1:6200 for all metabolic disorders, with an exceedingly low yield of fatty acid oxidation disorders, one of the main justifications for MS/MS screening in Caucasian populations [30].

We have presented the data of a single centre longitudinal registry so that they can be compared with others. Aside from economic evaluation all the criteria set by the SACHDNC [24] for extended NBS were addressed. We could demonstrate that physical and cognitive outcome of patients with presymptomatic diagnosis of metabolic disorders included in the current German screening panel is equally good as in patients with phenylketonuria. However, the specific evaluation of most of the rare disorders is still necessary and will require international registries and collaborative studies.

**Ethical approval**

The study was approved by the IRB of the Medical Faculty of the University Hospital Heidelberg (IRB code 104/2005) and parents of all participants gave written informed consent.

**Funding**

This extensive study over more than a decade was only made possible by the continuous and generous support of the Dietmar Hopp Foundation, St. Leon-Rot, Germany.

**Note**

* Dedicated to Dietmar Hopp on the occasion of his 70th birthday

**Additional material**

[Additional file 1: Supplementary Table S1](#)

**Abbreviations**

NBS: newborn screening; MS/MS: tandem-mass spectrometry

**Acknowledgements**

The authors are deeply indebted to the patients and their families for their participation and trust. Many thanks to all the colleagues who participated throughout the years by continuous interaction and exchange with the screening centre as well as by providing information on their patients, e.g. D. Haas, F. Hörster, S. Kölker and V. Konstantopoulou (Heidelberg), M. Baumgartner (Zürich), J. Hennemann (Berlin), and T. Rohrer (Homburg/Saar).

We would like to thank J. G. Oktay, D. Kohlmlüter, and C.-D. Langhans for excellent technical support of amino acid determination, organic acid analysis and acylcarnitine profiling, as well as S. Mengler for support in data management. Mutation analyses of different diseases were competently provided by J. Zschoeck, Institute of Human Genetics, University Hospital Heidelberg, Germany.

**Authors’ contributions**

All authors were involved in collection of data, critical revision and final approval of the article: GHF and ML conceived the idea. GHF is guarantor. PB and GH performed the statistical analysis. GG monitored data collection. ML and PB wrote the initial draft of the manuscript and all subsequent drafts with input from all co-authors. All authors had full access to all of the data and can take responsibility for the integrity of the data and the accuracy of the data analysis. The sponsor of the study had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit for publication.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Watson MS, Epstein C, Howell RR, Jones MC, Korf BR, McCabe ER, Simpson J. Developing a national collaborative study system for rare genetic diseases. Genet Med 2008; 10:325-329.

2. American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: Toward a Uniform Screening Panel and System-Executive Summary. Pediatrics 2006; 117:S296-S307.

3. Gemeinsamer Bundesausschuss. Beschluss über eine Änderung der Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über die Früherkennung von Krankheiten bei Kindern bis zur Vollendung des 6. Lebensjahres (Kinder-Richtlinien) zur Einführung des erweiterten Neugeborenen-Screenings, 2005 (Accessed May 18, 2011, at http://www.g-ba.de/informationen/beschluesse/zur-richtlinie/15/#170).

4. UK Newborn Screening Programme Centre: NHS Newborn Bloodspot Screening Programme, (Accessed May 18, 2011 at http://newbornbloodspot.screening.nhs.uk).

5. , Association Francaise pour le Dépistage et la Prévention des Handicaps de l’Enfant. (Accessed May 18, 2011 at http://www.afdphe.fr).

6. Padilla CD, Therrell BL: Newborn screening in the Asia Pacific region. J Inherit Metab Dis 2007, 30:490-506.

7. Wilson JM, Jungner G: Principles and Practice of Screening for Disease. Geneva, Switzerland: World Health Organization; 1968, Public Health Papers, No. 34.

8. The President’s Council on Bioethics. 2008. The Changing Moral Focus of Newborn Screening: An Ethical Analysis by The President’s Council on Bioethics, Washington, DC, December 2008, Accessed May 18, 2011 at http://bioethics.georgetown.edu/pcbe/reports/newborn_screening.

9. Andermann A, Blanquart I, Beauchamp S, Coteau I: Guiding Policy Decisions for Genetic Screening: Developing a Systematic and Transparent Approach. Public Health Genomics 2011, 14:9-16.

10. Andermann A, Blanquart I, Beauchamp S, Déry V: Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008, 86(4):317-319.
Organisation und Durchführung des Neugeborenscreenings auf angeborene Stoffwechselstörungen und Endokrinopathien in Deutschland. *Monatsschr Kinderheilkd* 2002, 150:1424-1440.

12. Schulze A, Lindner M, Kohlmüller D, Olgermüller K, Mayatepek E, Hoffmann GF: Expanded newborn screening for inborn errors of metabolism by electrospary ionization-tandem mass spectrometry: results, outcomes, and implications. *Pediatrics* 2003, 111:1399-1406.

13. Wilcken B, Haas M, Joy P, Wiley V, Bowling F, Carpenter K, Christodoulou J, Caveney D, Ellaway C, Fletcher J, Kirk EP, Lewis B, McGill J, Peters H, Pitt J, Raineri E, Yaplito-Lee J, Boneh A: Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. *Pediatrics* 2001, 124:e241-248.

14. Nennstiel-Ratzel U, Arens Z, Maier EM, Knerr N, Baumkotter J, Roschinger W, Liebl B, Hadorn HB, Roscher AA, von Kries R: Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c.985A>G identified by neonatal screening. *Mol Genet Metab* 2005, 85(2):157-159.

15. Wilcken B, Haas M, Joy P, Wiley V, Chaplin M, Black C, Fletcher J, McGill J, Boneh A: Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. *Lancet* 2007, 369:43-47.

16. Pollitt RJ, Leonard JV: Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. *Arch Dis Child* 1998, 79:116-119.

17. Derks TG, Rejingoud DJ, Waterham HR, Gerver WJ, van den Berg MP, Sauer PJ, Smit GP: The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: clinical presentation and outcome. *J Pediatr* 2006, 148:665-670.

18. Wilcken B, Hammond J, Silnik M: Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. *Arch Dis Child* 1994, 70:410-412.

19. Kölker S, Garbade SF, Greenberg CR, Leonard JV, Saudubray JM, Cassival M, Caswell M, Burline AB, Lagler F, Maier EM, Schwahn B, Taktali A, Dursun A, Coskun T, Chalmers RA, Koeller DM, Zschocke J, Christensen E, Burgard P, Hoffmann GF: Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. *Pediatr Res* 2006, 59:840-847.

20. Kölker S, Garbade SF, Boy N, Maier EM, Meissner T, Mühlhausen C, Hennemayer JB, Lucke T, Habelle J, Baumkötter J, Haller W, Muller E, Zschocke J, Burgard P, Hoffmann GF: Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by newborn screening in Germany. *Pediatr Res* 2007, 62:357-363.

21. Griggs RC, Batshaw M, Dunkle K, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA: Rare Diseases Clinical Research Network: Clinical research for rare disease: opportunities, challenges, and solutions. *Mol Genet Metab* 2008, 95:206-212.

22. Wilcken B: The consequences of extended newborn screening programmes: Do we know who needs treatment? *J Inherit Metab Dis* 2008, 31:173-177.

23. Picciniglio C, Thomas N, Yager C, Gallacher PR, Hsia C, Mattie A, Day-Salvatore DL, Forbes BJ, Duarte (DG) galactosemia: a pilot study of biochemical and neurodevelopmental assessment in children detected by newborn screening. *Mol Genet Metab* 2008, 95:206-212.

24. Perrin JM, Knapp AA, Browning MF, Corneau AM, Green NS, Lipstein EA, Metterville DR, Prosser L, Quelly D, Kemper AR: An evidence development process for newborn screening. *Genet Med* 2010, 12:131-134.

25. Evaluation of population newborn screening practices for rare disorders in Member States of the European Union, The tender No EHIC/2009/Health/ 09 (Accessed May 18, 2011, at http://www.ojrd.com/content/6/1/44)

26. Wilcken B: Expanded newborn screening: reducing harm, assessing benefit. *J Inherit Metab Dis* 2010, 33(Suppl 2): S205-S210

27. Lindner M, Abdoh G, Fang-Hoffmann J, Shabek N, Al-Sayari M, Al-Janahi M, Ho S, Abdeelahman MO, Ben-Omran T, Benner A, Schulze A, Al-Rifai H, Al-Thani G, Hoffmann GF: Implementation of extended neonatal screening and a metabolic unit in the State of Qatar: developing and optimizing strategies in cooperation with the Neonatal Screening Center in Heidelberg. *J Inherit Metab Dis* 2007, 30:522-529.

28. Gan-Schreier H, Kebbewar M, Fang-Hoffmann J, Wilrich J, Abdoh G, Ben-Omran T, Shahbek N, Benner A, Al Rifai H, Al Khal AL, Lindner M, Zschocke J, Hoffmann GF: Newborn population screening for classic homocystinuria by determination of total homocysteine from Guthrie cards. *J Pediatr* 2010, 156:427-432.

29. Demirkil M, Çelik S, Gökşay G, Özer I, Baykal T, Karadağ H, Köse R: Expanded newborn screening experience in Istanbul. *J Inherit Metab Dis* 2007, 30(Suppl 1):3.

30. Niu DM, Chien YH, Chiang CC, Ho HC, Hwu WL, Kao SM, Chang SH, Kao CH, Liu TT, Chiang H, Hisao KJ: Nationwide Survey of Extended Newborn Screening by Tandem Mass Spectrometry in Taiwan. *J Inherit Metab Dis* 2010, 33(Suppl 2):5295-5305.

Cite this article as: Lindner et al.: Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany *Orphanet Journal of Rare Diseases* 2011 6:44.